Government-Owned Inventions; Availability for Licensing, 43393 [2017-19591]

Download as PDF Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices Potential Commercial Applications: • Therapeutics for hypertension • Therapeutics for anxiety disorders • Therapeutics for sleep disorders Development Stage: • In vivo data available Inventors: George Kunos and Alexandros Makriyannis (both of NIAAA) Intellectual Property: HHS Reference No. E–211–2006/0–US–06. • U.S. Patent 8,293,724 filed April 6, 2010, issued October 23, 2012. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@nih.gov. Collaborative Research Opportunity: The National Institute of Environmental Health Sciences seeks statements of capability or interest from parties interested in collaborative research to further develop and evaluate, please contact Peg Koelble, Office of Technology Transfer, National Heart, Lung and Blood Institute, koelblep@ nhlbi.nih.gov, 301–594–4095. Dated: September 7, 2017. Michael Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2017–19590 Filed 9–14–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240–627–3705, chris. kornak@nih.gov. Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office (TTIPO), 5601 Fishers Lane, Suite 6D, MSC 9804, Rockville, mstockstill on DSK30JT082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 17:07 Sep 14, 2017 Jkt 241001 43393 No. PCT/US2017/021573 filed on 03/09/ 2017. Licensing Contact: Chris Kornak, 240– 627–3705, chris.kornak@nih.gov. Collaborative Research Opportunity: The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in Recombinant HIV-1 Envelope Proteins collaborative research to further develop and Their Use the technology. In particular, NIAID is Description of Technology: Millions of interested in partnerships utilizing vector vaccine platforms for expressing people are infected with HIV-1 these immunogens. worldwide. In the U.S., there are about However, NIAID is willing to discuss 30,000 new cases of HIV infection other applications of this technology. reported annually. Currently, there are For collaboration opportunities, please effective, anti-retroviral therapeutics contact Chris Kornak, 240–627–3705, available to treat or prevent HIV chris.kornak@nih.gov. infection. However, available antiretroviral therapeutics require life-long Dated: September 7, 2017. administration. Suzanne Frisbie, During infection, proteases of the host Deputy Director, Technology Transfer and cell cleave gp160 into gp120 and gp41. Intellectual Property Office, National Institute Gp41 is an integral membrane protein, of Allergy and Infectious Diseases. while gp120 protrudes from the mature [FR Doc. 2017–19591 Filed 9–14–17; 8:45 am] virus. Together gp120 and gp41 BILLING CODE 4140–01–P aggregate as trimers that make up the HIV-1 envelope (‘‘Env’’) spike, which is a target for neutralizing antibodies. DEPARTMENT OF HEALTH AND NIAID researchers have constructed a HUMAN SERVICES recombinant HIV-1 trimer immunogen. National Institutes of Health In particular, the recombinant gp120 protein in the trimer is stabilized in a closed conformation, preventing it from National Institute on Deafness and Other Communication Disorders; binding to CD4. The advantage of the Notice of Closed Meetings closed conformation is that it can stabilize the epitopes that bind to Pursuant to section 10(d) of the broadly neutralizing antibodies, Federal Advisory Committee Act, as minimize the binding of gp120 with amended, notice is hereby given of the weakly or non-neutralizing antibodies, following meetings. and prevent conformational changes The meetings will be closed to the induced by CD4 as well as immunogen public in accordance with the sequestration by CD4 in vivo. Research provisions set forth in sections has also indicated that recombinant Env 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., ectodomain trimers can induce higher as amended. The grant applications and neutralizing antibody titers than wild the discussions could disclose type Env trimers in animal models. confidential trade secrets or commercial This technology is available for property such as patentable material, licensing for commercial development and personal information concerning in accordance with 35 U.S.C. 209 and 37 individuals associated with the grant CFR part 404, as well as for further applications, the disclosure of which development and evaluation under a would constitute a clearly unwarranted research collaboration. invasion of personal privacy. Potential Commercial Applications: Name of Committee: National Institute on • HIV-1 immunogen Deafness and Other Communication • New methods for isolating broadly Disorders Special Emphasis Panel; Chemical neutralizing antibodies Senses Fellowship Review. Competitive Advantages: Date: October 11, 2017. • A new strategy in inducing immune Time: 12:30 p.m. to 3:00 p.m. response against HIV-1 Agenda: To review and evaluate grant applications. Development Stage: Place: National Institutes of Health. • Pre-Clinical; Proof-of-concept Neuroscience Center, 6001 Executive studies in nonhuman primate Boulevard, Rockville, MD 20852 (Telephone models Conference Call). Inventors: Contact Person: Sheo Singh, Ph.D., Paolo Lusso, NIAID, NIH Scientific Review Officer, Scientific Review Peng Zhang, NIAID, NIH Branch, Division of Extramural Activities, Publications: Pending. 6001 Executive Blvd., Room 8351, Bethesda, Intellectual Property: HHS Reference MD 20892, 301–496–8683, singhs@ No. E–102–2016/0—PCT Application nidcd.nih.gov. MD 20892, tel: 301–496–2644, fax: 240– 627–3117. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 E:\FR\FM\15SEN1.SGM 15SEN1

Agencies

[Federal Register Volume 82, Number 178 (Friday, September 15, 2017)]
[Notices]
[Page 43393]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-19591]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705, 
chris.kornak@nih.gov. Licensing information and copies of the U.S. 
patent applications listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office (TTIPO), 5601 Fishers Lane, Suite 6D, MSC 
9804, Rockville, MD 20892, tel: 301-496-2644, fax: 240-627-3117. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Recombinant HIV-1 Envelope Proteins and Their Use

    Description of Technology: Millions of people are infected with 
HIV-1 worldwide. In the U.S., there are about 30,000 new cases of HIV 
infection reported annually. Currently, there are effective, anti-
retroviral therapeutics available to treat or prevent HIV infection. 
However, available anti-retroviral therapeutics require life-long 
administration.
    During infection, proteases of the host cell cleave gp160 into 
gp120 and gp41. Gp41 is an integral membrane protein, while gp120 
protrudes from the mature virus. Together gp120 and gp41 aggregate as 
trimers that make up the HIV-1 envelope (``Env'') spike, which is a 
target for neutralizing antibodies.
    NIAID researchers have constructed a recombinant HIV-1 trimer 
immunogen. In particular, the recombinant gp120 protein in the trimer 
is stabilized in a closed conformation, preventing it from binding to 
CD4. The advantage of the closed conformation is that it can stabilize 
the epitopes that bind to broadly neutralizing antibodies, minimize the 
binding of gp120 with weakly or non-neutralizing antibodies, and 
prevent conformational changes induced by CD4 as well as immunogen 
sequestration by CD4 in vivo. Research has also indicated that 
recombinant Env ectodomain trimers can induce higher neutralizing 
antibody titers than wild type Env trimers in animal models.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications:
     HIV-1 immunogen
     New methods for isolating broadly neutralizing antibodies
Competitive Advantages:
     A new strategy in inducing immune response against HIV-1
Development Stage:
     Pre-Clinical; Proof-of-concept studies in nonhuman primate 
models
Inventors:
    Paolo Lusso, NIAID, NIH
    Peng Zhang, NIAID, NIH

    Publications: Pending.
    Intellectual Property: HHS Reference No. E-102-2016/0--PCT 
Application No. PCT/US2017/021573 filed on 03/09/2017.
    Licensing Contact: Chris Kornak, 240-627-3705, 
chris.kornak@nih.gov.
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further develop the technology. In 
particular, NIAID is interested in partnerships utilizing vector 
vaccine platforms for expressing these immunogens.
    However, NIAID is willing to discuss other applications of this 
technology. For collaboration opportunities, please contact Chris 
Kornak, 240-627-3705, chris.kornak@nih.gov.

    Dated: September 7, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-19591 Filed 9-14-17; 8:45 am]
 BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.